Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes

摘要

Medicaments and pharmaceutical kits comprising an LTB4 antagonist of formula (I)a tautomer thereof or a pharmaceutically acceptable salt thereof, and methods of treating or preventing cystic fibrosis, diseases caused by increased expression of mucin genes in the bronchial or gastrointestinal epithelium, or hyperplasia of goblet cells induced by toxins of products of pathogenic bacteria in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of an LTB4 antagonist of formula (I).